IO Biotech Q2 net loss $21.2M; Phase 3 melanoma trial reaches 225-patient milestone; $75M private placement closed

IO Biotech, Inc.

2023-Q2 EPS reported -$1.33

Net loss of $21.2M (vs $18.5M Q2 2022); R&D spend $16.5M on Phase 3 trial execution.
Cash and equivalents $110.1M; expected to fund operations into Q4 2025.
Phase 3 IOB-013/KN-D18 enrolled 225 patients; target raised to 380, full enrollment by end 2023.
Interim ORR analysis one year post 225 randomized may support US accelerated BLA submission.
Appointed Heidi Hunter to Board; Priyanka Belawat resigned; closed $75M private placement (37M shares+warrants).

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Priyanka Belawat

Director

IOBTQ · IO Biotech, Inc.

Effective: 2023-08-07
Filed: August 11, 2023, 7:59 PM ET

On August 7, 2023, Priyanka Belawat, a member of the Board of Directors of the Company, notified the Company of her resignation from the Board, effective that same date.

Appointed

Heidi Hunter

Class II director

IOBTQ · IO Biotech, Inc.

Effective: 2023-08-11
Filed: August 11, 2023, 7:59 PM ET

On August 8, 2023, the Company appointed Heidi Hunter as a Class II director of the Company, effective as of August 11, 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IO Biotech, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $21.2 million.

Period: second quarter ended June 30, 2023
Net income: Net loss for the three months ended June 30, 2023 was $21.2 million
Result: reported results

Exact text from the filing

Net loss for the three months ended June 30, 2023 was $21.2 million

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Priyanka Belawat resigned as Director at IO Biotech, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 7, 2023, Priyanka Belawat, a member of the Board of Directors of the Company, notified the Company of her resignation from the Board, effective that same date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Heidi Hunter was appointed as Class II director at IO Biotech, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

On August 8, 2023, the Company appointed Heidi Hunter as a Class II director of the Company, effective as of August 11, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-209874

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.